Sanofi To Sell 16 Consumer Healthcare Products to Stada

By Miranda Greenberg -

July 1, 2021

Sanofi has agreed to sell a portfolio of 16 local and regional consumer healthcare brands in countries predominantly in Europe to Stada, a Bad Vilbel, Germany-based specialty pharma, generics, and non-prescription consumer healthcare company, for an undisclosed amount.

The agreement covers the registrations, trademarks, and related commercial rights of the 16 products across Europe. Most of the acquired portfolio’s annual turnover is currently achieved in five European countries: Germany, France, Spain, Italy, and Poland.

The portfolio includes cold and flu, skincare, and food supplement brands. Cough and cold brands account for more than half of the acquired portfolio’s sales, and derma brands around one third.

The transaction covers 16 brands, including: Mitosyl ointment and wipes for daily care of sensitive areas and protection against diaper irritation; Silomat dry-cough remedies; Frubiase nutritional supplements for athletes; Modafen cold- and flu-relief tablets; and the Viscontour allergen-free skincare product range.

Other acquired brands include: Lisomucil cough syrup in Italy; Bronchoforton ointment in Germany; Bronchokod syrup in France; and Brolene eye drops and ointment in the UK and Ireland. Also included are: Antigongestiva Cusi (treatment of minor skin irritations) and Rinocusi (a nasal ointment) in Spain; Acodin (cough-cold treatment) in Poland; Nasobol (cold-cough treatment) in Switzerland; and Sedotussin (cough treatment) in Germany.

Stada will also explore synergy potential from transferring manufacturing of certain brands into the group’s existing supply-chain network.

No manufacturing assets or employees are included in the transaction, which is scheduled to close in the third quarter of 2021, subject to approval of relevant regulatory authorities and other customary closing conditions.

The acquisition from Sanofi comes after Stada acquired 15 consumer healthcare brands across more than 40 countries and multiple therapeutic areas from GlaxoSmithKline last year (2020). Stada also recently strengthened its portfolio of vitamin, mineral, and supplement products by acquiring the Czech healthcare company, Walmark, which has an international footprint.

Source: Sanofi and Stada